The CTFPHC recognizes that women have various degrees of glucose intolerance during pregnancy and that a certain proportion will have adverse outcomes and could benefit from screening. Universal screening with the 50g GCT has not been demonstrated to be superior, yet it can carry considerable costs. Pending the results of ongoing studies on the sensitivity and specificity of other screening manoeuvres, factors such as clinical judgement (assessment of risk factors and pregnancy evolution) and available resources should be taken into account in choosing a screening strategy.